Winton Group LTD Editas Medicine, Inc. Transaction History

Winton Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$7.03 - $11.53 $2,151 - $3,528	-306 Reduced 1.45%	20,824 $150,000
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $9,992 - $15,865	1,201 Added 6.03%	21,130 $187,000
Q3 2022 Nov 10, 2022	SELL	$12.16 - $19.42 $30,071 - $48,025	-2,473 Reduced 11.04%	19,929 $244,000
Q2 2022 Aug 10, 2022	BUY	$9.99 - $21.35 $47,612 - $101,754	4,766 Added 27.02%	22,402 $265,000
Q1 2022 May 11, 2022	BUY	$14.08 - $27.63 $46,562 - $91,372	3,307 Added 23.08%	17,636 $335,000
Q4 2021 Feb 10, 2022	BUY	$26.55 - $40.57 $380,434 - $581,327	14,329 New	14,329 $380,000
Q1 2021 Jul 21, 2021	SELL	$39.71 - $90.58 $306,680 - $699,549	-7,723 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$27.07 - $84.35 $1.02 Million - $3.18 Million	-37,661 Reduced 82.98%	7,723 $541,000
Q3 2020 Oct 30, 2020	BUY	$28.06 - $37.16 $952,973 - $1.26 Million	33,962 Added 297.34%	45,384 $1.27 Million
Q2 2020 Aug 05, 2020	SELL	$18.5 - $34.34 $262,015 - $486,357	-14,163 Reduced 55.36%	11,422 $338,000
Q1 2020 May 11, 2020	BUY	$14.88 - $32.78 $380,704 - $838,676	25,585 New	25,585 $507,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.